Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

A federal panel’s controversial recommendation that healthy men older than 50 avoid a PSA-based prostate screening test is drawing scorn from some doctors. The U.S. Preventive Services Task Force, an ...

or on the link below. Prostate-specific antigen (PSA) is both a blessing and a curse for prostate cancer. It is a blessing because it makes prostate cancer one of the few cancers with a reliable serum ...

To check for possible prostate cancer, physicians most often use prostate-specific antigen (PSA) tests and digital rectal exams (DREs). For a firm diagnosis, they use core needle biopsies. This page ...

Add Yahoo as a preferred source to see more of our stories on Google. Writer Nick Harding has a blood test at a GFCT prostate cancer screening event at the Nelson Club in Warwick - Andrew Fox A few ...

From AI-generated biopsy reports to new imaging techniques, these are the latest developments in advanced prostate cancer research that your doctor may be keeping tabs on. Much of managing advanced ...

The Decipher Prostate Metastatic test is now available for metastatic prostate cancer, covered by Medicare for all risk levels. It helps clinicians determine which patients may benefit from treatment, ...

Patrick Shannon of Kenhorst was relishing a new phase of life — retirement from his careers in construction and security — when his primary care doctor called with unexpected news. Shannon’s recent ...

A new at-home saliva test could help identify men with a high risk of prostate cancer more accurately than blood tests, leading to earlier diagnosis and more successful treatment. Prostate cancer is ...

Researchers at Vanderbilt and the University of Michigan have shown that a simple at-home urine test for prostate cancer screening is highly accurate. The exciting new results, published in The ...

SAN FRANCISCO--(BUSINESS WIRE)--Artera, a developer of multimodal AI-based prognostic and predictive cancer tests, today announced the commercial launch of the ArteraAI Prostate Test (Post‑RP) for ...